Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat
1 Laboratoire de Pharmacologie, Centre de Pharmacologie et Biotechnologies pour la Santé-Unite Mixte de Recherche 5160 Centre National de la Recherche Scientifique, Faculté de Médecine, 34060 Montpellier; 2 INNODIA S.A., 34000 Montpellier; 3 Institut National de la Santé et de la Recherche Médicale...
Saved in:
Published in | American journal of physiology: endocrinology and metabolism Vol. 287; no. 3; pp. E463 - E471 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Physiological Society
01.09.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 1 Laboratoire de Pharmacologie, Centre de Pharmacologie et Biotechnologies pour la Santé-Unite Mixte de Recherche 5160 Centre National de la Recherche Scientifique, Faculté de Médecine, 34060 Montpellier; 2 INNODIA S.A., 34000 Montpellier; 3 Institut National de la Santé et de la Recherche Médicale U341, Service de Diabétologie, 75004 Paris; 4 Laboratoire de Biologie Cellulaire et Moléculaire, bÂtiment des Biotechnologies, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas; and 5 Laboratoire de Physiopathologie de la Nutrition, Centre National de la Recherche Scientifique UMR 7059, Université Paris 7, 75005 Paris, France
Submitted 11 April 2003
; accepted in final form 2 March 2004
ID-1101 (4-hydroxyisoleucine), an amino acid extracted from fenugreek seeds, exhibits an interesting glucose-dependent insulin-stimulating activity. The present study was undertaken to investigate a possible extrapancreatic effect of ID-1101 on insulin signaling and action besides its previously described insulinotropic action. Insulin-sensitizing effects of ID-1101 were investigated in rat in vivo by three different approaches: 1 ) using euglycemic hyperinsulinemic clamps in two different rat models of insulin resistance, i.e., Zucker fa/fa rats and rats fed a sucrose-lipid diet; 2 ) measuring liver and muscle phosphatidylinositol (PI) 3-kinase activity after an acute injection of ID-1101 in normal and insulin-resistant diabetic rats; and 3 ) after chronic treatment in two rat models of insulin resistance. Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats. Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats. Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats. These findings clearly demonstrate that ID-1101 can reduce insulin resistance through activation of the early steps of insulin signaling in peripheral tissues and in liver. In summary, ID-1101, besides its insulinotropic effect, directly improves insulin sensitivity, making it a potentially very valuable therapeutic agent for diabetes treatment.
insulin resistance; phosphatidylinositol 3-kinase; euglycemic hyperinsulinemic clamp; diabetes; obesity
Address for reprint requests and other correspondence: C. Broca, Laboratoire de Pharmacologie, CPBS-UMR 5160 CNRS, Faculté de Médecine, Institut de Biologie, Boulevard Henri IV, 34060 Montpellier cedex 1, France (E-mail: christophe.broca{at}univ-montp1.fr ). |
---|---|
ISSN: | 0193-1849 1522-1555 |
DOI: | 10.1152/ajpendo.00163.2003 |